Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 6/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 4/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HBB | P68871 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29644533 | 1.00 | CA2 (0.41) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL5695479 | 1.00 | CA2 (0.41) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL7948821 | 0.81 | CA2 (0.41) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL95677 | 0.81 | CA2 (0.44) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| Iodide SCHEMBL29719539 | 0.79 | MAOB (0.37) | SIGMAR1NISCHCHRM2CHRM4CHRM5 | |
| SCHEMBL5845061 | 0.76 | ESR1 (0.56) | — | |
| SCHEMBL28452012 | 0.76 | HTR2C (0.48) | HTR1AADRA2AADRA2BADRA2CHTR1D | |
| SCHEMBL460126 | 0.75 | CA2 (0.44) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL30070640 | 0.75 | CA2 (0.44) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL29462397 | 0.74 | CA2 (0.46) | CA2HTR1ASIGMAR1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0115142-B1 | CHROMAN COMPOUNDS | ICI AMERICAS INC. (US) | 1986-11-05 | — | — | EP | claimed |
| EP-0115142-A1 | Chroman compounds | ICI AMERICAS INC. (US) | 1984-08-08 | — | — | EP | claimed |
| CN-108383822-A | The preparation method of the chloro- 1- of 2- (the fluoro- 3,4- dihydros -2H-1- chromenes -2- bases of 6-) ethyl ketone | 浙江车头制药股份有限公司 | 2018-08-10 | — | — | CN | disclosed |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-7425631-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7199244-B2 | Cyclic amine derivatives and methods of use | AMGEN (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1633743-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | Amgen, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1631542-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | Amgen, Inc. (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | AMGEN INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2004092116-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004092164-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| EP-0707007-B1 | (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane as CNS active agent | MERCK PATENT GMBH (DE) | 2001-12-12 | — | — | EP | disclosed |
| EP-1123933-A1 | 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane as CNS active agent | MERCK PATENT GmbH (DE) | 2001-08-16 | — | — | EP | disclosed |
| US-5767132-A | CENTRAL NERVOUS SYSTEM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-06-16 | — | — | US | disclosed |
| EP-0707007-A1 | Amino(thio)ether derivatives as CNS active agents | MERCK PATENT GmbH (DE) | 1996-04-17 | — | — | EP | disclosed |
| EP-0115142-B1 | CHROMAN COMPOUNDS | ICI AMERICAS INC. (US) | 1986-11-05 | — | — | EP | disclosed |
| EP-0115142-A1 | Chroman compounds | ICI AMERICAS INC. (US) | 1984-08-08 | — | — | EP | disclosed |
| US-4268446-A | REACTING A HYDROQUINONE, LEWIS ACID OR BASE DERIVATIVE AND A NITRILE IN THE PRESENCE OF AN INERT SOLVENT | BASF AKTIENGESELLSCHAFT (DE) | 1981-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | CA2 1204/4885HTR1A 1992/4885SIGMAR1 846/4885 |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | LTC4S, PTGES, LTB4R2 | CA2 1204/4885HTR1A 1992/4885SIGMAR1 846/4885 |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | PTGIS, BDKRB2, LTC4S | CA2 2607/4885HTR1A 633/4885SIGMAR1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.